alexa Role of Cancer and Chemotherapy in the Incidence of Thrombocytopenia | OMICS International
ISSN : 2153-2435
Pharmaceutica Analytica Acta
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Role of Cancer and Chemotherapy in the Incidence of Thrombocytopenia

Bassam Abdul Rasool Hassan*

Clinical Pharmacy Discipline,School of Pharmaceutical Science,University of Sains Malaysia,Malaysia

*Corresponding Author:
Bassam Abdul Rasool Hassan
Clinical Pharmacy Discipline
School of Pharmaceutical Science
University of Sains Malaysia
11800, Minden, Penang, Malaysia
Tel: +60164230950
E-mail: [email protected]

Received date: November 16, 2013; Accepted date: November 19, 2013; Published date: November 22, 2013

Citation: Hassan BAR (2013) Role of Cancer and Chemotherapy in the Incidence of Thrombocytopenia. Pharmaceut Anal Acta 4:e157. doi: 10.4172/2153-2435.1000e157

Copyright: © 2013 Hassan BAR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutica Analytica Acta

Introduction

Thrombocytopenia is a term used to indicate unusual reduction or drop in platelets numbers. These platelets play a major role in clot formation during bleeding in order to block blood lost. Therefore, a reduction in platelet number will mainly lead to incidence of bleeding, which ranges from mild bleeding from small blood vessels to severe bleeding from large blood vessels. Severe bleeding in the presence of severe thrombocytopenia or when is coupled with other clotting disorders can lead to serious morbidity or death. Thrombocytopenia is a common problem experience by cancer patients, which usually is a result of the use of conventional chemotherapy, and at times, is a dose limiting factor for chemotherapy administration. About 10-25% of solid cancer patients (specifically: breast cancer, ovarian and germ cell) who were treated with intensive chemotherapy suffer from incidence of thrombocytopenia. Even though, incidence of thrombocytopenia among acute leukemia patients is higher than its incidence among other types of cancer [1-8].

Levels of Thrombocytopenia

The normal range of the platelets is between 150,000 and 450,000 cells per microliter of blood (i.e. 150-450×109/L), while thrombocytopenia could be classified into three levels as follows:

1. ild thrombocytopenia if platelets count <150 and ≥ 100×109/L.

2. oderate thrombocytopenia if platelets count<100 and ≥ 50×109/L.

3. Severe thrombocytopenia if platelets count <20×109/L [9,10].

4. Association of Thrombocytopenia with Chemotherapy

Thrombocytopenia is a harmful side effect of chemotherapy, since it will cause incidence of bleeding among solid cancer patients who were treated with chemotherapy from vital organ mainly the brain. Chemotherapies, specifically the antimetabolites and alkylating agents, caused thrombocytopenia by various mechanisms, either by suppressing megakaryopoiesis, i.e. bone marrow suppression or by direct damaging of the platelets [7,11-13].

Thrombocytopenia and Solid Cancer

The relationship between hemorrhage and thrombocytopenia in leukemic patient was first described in 1962. While among solid cancer patients, presence of thrombocytopenia was reported later [14]. Among those patients, i.e. solid cancer patients, the main cause for incidence of thrombocytopenia is its metastasis to bone marrow. The most frequent types of solid tumors that metastasis to bone are breast, lung and prostate cancers. These cancers when metastasized to bone marrow will lead to bone marrow suppression, resulting in neutropenia and thrombocytopenia with serious morbidity and mortality [15]. Even though the incidence of hemorrhage among solid cancer patients still consider low when it is compared with hematological malignant, unless all the above characteristic are all present [7].

Conclusion

Therefore, it is an obligate and/or recommended subject for the ongoing on preclinical studies to focus on the incidence of thrombocytopenia among cancer patients.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11704
  • [From(publication date):
    November-2013 - Dec 12, 2017]
  • Breakdown by view type
  • HTML page views : 7923
  • PDF downloads : 3781
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version